Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Generate Biomedicines, Inc.

NASDAQ: GENB · Life Sciences · 3 alerts · CIK 2100782

Share price
$10.49Close, Nov 16
Market cap
$1.35B
Shares outstanding
129.1MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Generate Biomedicines, Inc. filings on SEC EDGAR ↗

7:16 AM ET 8-K
Financial Results

Generate Biomedicines Financial Results

Generate Biomedicines reported third quarter 2026 financial results, highlighting a cash position of $404.2 million and progress in its Phase 3 asthma studies for GB-0895. The company also noted a significant collaboration with Zealand Pharma in obesity and metabolic diseases with total potential milestones of nearly $1.2 billion.

“Our third quarter results reflect both strong execution across all of our clinical programs and our continued efforts to push the frontiers of programmable biology and therapeutic intelligence. We are making strong progress with GB-0895 in severe asthma, and the data we shared at ERS in COPD further demonstrated the sustained pharmacological activity to support robust modulation of key biomarkers and twice-a-year dosing.”

Mike Nally, chief executive officer of Generate Biomedicines

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.